Denintuzumab mafodotin

Denintuzumab mafodotin (SGN-19A or SGN-CD19A) (INN) is a humanized monoclonal antibody-drug conjugate designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent. This drug was developed by Seattle Genetics, Inc.'-mexi-' (melanoma): Ecromeximab§ Denintuzumab mafodotin (SGN-19A or SGN-CD19A) (INN) is a humanized monoclonal antibody-drug conjugate designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent. This drug was developed by Seattle Genetics, Inc. Denintuzumab refers to the anti-CD19 antibody, and mafodotin refers to MMAF and the chemical linkage. The drug is currently in phase I clinical trials.Preliminary phase I results for B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphocytic leukemia (B-ALL) are being presented at the ASH medical conference Dec 2015. A separate randomized phase 2 trial started in 2015 to evaluate SGN-CD19A in combination with R-ICE chemotherapy for second-line DLBCL. A phase 2 clinical trial in front-line DLBCL is started in 2016. Both trials were terminated by the Sponsor based on portfolio prioritization.